Liven Pharma cuts quarterly loss by 76% to Rs7m

Liven Pharma Limited reported a net loss of Rs7.37 million for the quarter ended September 30, 2026, down 75.56% from Rs30.16 million a year earlier, Mettis Global said. Its basic and diluted loss per share improved to Rs0.07 from a restated Rs0.28.

Revenue increased 62.04% to Rs14.29 million, but a more than threefold rise in cost of sales left the company with a gross loss of Rs2.57 million, versus a gross profit of Rs3.93 million in the comparable quarter. Lower administrative, selling and other expenses helped reduce the operating loss, while other income climbed to Rs7.60 million from Rs4,032. A Rs2.71 million tax credit further reduced the quarterly loss, although the company remained loss-making.